Clinical Trials: Regulatory Query Response Handling

Best Practices for Responding to Regulatory Queries

Posted on digi By digi

Regulatory queries are formal requests from health authorities such as the FDA, EMA, Health Canada, or TGA, seeking clarification or additional information regarding a submitted application—be it an IND, NDA, BLA, ANDA, CTA, or marketing authorization. These queries can come in various forms: Information Requests (IRs), Deficiency Letters, 483s, or Clarification Requests. The way a sponsor addresses these queries often determines the fate of the submission—approval, delay, or rejection.

Click to read the full article.

Regulatory Query Response Handling, Regulatory Submissions and Approvals

How to Manage Deficiency Letters During Review

Posted on digi By digi

Regulatory deficiency letters—such as Complete Response Letters (CRLs) from the FDA, List of Questions (LoQs) from EMA, or Clarifaxes from Health Canada—are formal communications issued when a health authority identifies gaps, deficiencies, or concerns in a submitted dossier. These letters signal that the application cannot proceed to approval unless the stated issues are resolved to the agency’s satisfaction.

Click to read the full article.

Regulatory Query Response Handling, Regulatory Submissions and Approvals

Root Cause Analysis in Regulatory Response Preparation

Posted on digi By digi

Regulatory authorities such as the FDA, EMA, or PMDA may issue deficiency letters, complete response letters (CRLs), or requests for clarification during the review of an IND, NDA, BLA, CTA, or ANDA. These communications often highlight gaps in the data, inconsistencies in the Common Technical Document (CTD), or procedural nonconformities. Without an accurate understanding of the underlying cause, responses may be superficial and risk rejection or prolonged review cycles.

Click to read the full article.

Regulatory Query Response Handling, Regulatory Submissions and Approvals

Constructing a Response Matrix for Reviewer Comments

Posted on digi By digi

During regulatory review of applications such as INDs, NDAs, ANDAs, BLAs, CTAs, or MAAs, health authorities like the FDA, EMA, and Health Canada issue comments or questions that must be addressed before approval. These may arrive as formal deficiency letters (e.g., Complete Response Letter or List of Questions) or informal Information Requests (IRs).

Click to read the full article.

Regulatory Query Response Handling, Regulatory Submissions and Approvals

Time Management and Submission Timelines for Responses

Posted on digi By digi

When health authorities such as the FDA, EMA, MHRA, PMDA, or Health Canada issue questions during the review of a submission (IND, NDA, BLA, ANDA, CTA, MAA), they often trigger specific timelines for the sponsor to respond. These timelines vary depending on the agency, the type of communication, and the review pathway.

Click to read the full article.

Regulatory Query Response Handling, Regulatory Submissions and Approvals

Documentation Standards in Query Response Letters

Posted on digi By digi

During the lifecycle of regulatory submissions, sponsors and applicants often receive queries, comments, or deficiency letters from global health authorities such as the FDA (United States), EMA (Europe), PMDA (Japan), Health Canada, and others. These questions may pertain to the Chemistry, Manufacturing and Controls (CMC), Clinical, Nonclinical, or Labeling sections of a submission, and require well-documented responses to ensure a smooth review process.

Click to read the full article.

Regulatory Query Response Handling, Regulatory Submissions and Approvals

Handling Multiple Rounds of Regulatory Feedback

Posted on digi By digi

Drug development and approval processes are rarely linear. After an initial submission—be it an IND, NDA, BLA, or CTA—sponsors often receive a first round of questions from regulators. However, this may not be the end. Agencies like the FDA, EMA, and PMDA frequently issue multiple rounds of feedback, especially for complex or novel therapies.

Click to read the full article.

Regulatory Query Response Handling, Regulatory Submissions and Approvals